Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11241 clinical trials
UPENN Case Test Trial 5 (Do Not Make Any Changes)

UPENN Case Test Trial 5 (Do Not Make Any Changes)

  • 0 views
  • 24 Apr, 2025
  • 1 location
Optimization of the Targeted Anticancer Therapies

The study includes an observational pharmacokinetic study and an interventional medication adherence study. The purpose of this study is 1) to describe the concentration-time profiles of targeted anticancer drugs and to characterize the concentration-effect/toxicity relationships in the target population of patients (observational study) and 2) to characterize patterns of adherence …

cancer
cancer treatment
cancer therapy
  • 0 views
  • 05 Aug, 2020
Study to Assess Safety Tolerability Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Prospective, open-label, uncontrolled and multicenter phase I-II study in SCLC patients with ECOG PS 0-1 who have failed one prior platinum-containing line but no more than one chemotherapy-containing line. The study will be divided into two parts: a dose-ranging phase I with escalating doses of PM01183 in combination with a …

measurable disease
carcinoma
progressive disease
lung cancer
hair thinning
  • 0 views
  • 16 Feb, 2024
  • 5 locations
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

  • 0 views
  • 16 Feb, 2024
  • 2 locations
Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Locally-Advanced Breast Cancer

The objective of this study is to demonstrate the feasibility of novel MRI-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.

carcinoma
advanced breast cancer
breast cancer staging
potassium
  • 0 views
  • 16 Feb, 2024
  • 1 location
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

At the same time, combined with four generations of CAR-T cells and PD1 monoclonal antibody, PD1 / PDL1 signal pathway was blocked, anti-tumor effect of CAR-T was improved, and immune response and long-term remission rate of DLBCL were improved.

diffuse large b-cell lymphoma
lymphoma
ejection fraction
refractory b-cell non-hodgkin lymphoma
pet/ct scan
  • 0 views
  • 05 Aug, 2020
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

This phase III trial aims to compare the progression free survival (PFS) and safety of fulvestrant or capecitabine as maintenance therapy after first-line combined chemotherapy in hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer.

kidney function tests
hair thinning
cancer
chemotherapy regimen
erbb2
  • 0 views
  • 16 Feb, 2024
  • 7 locations
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

This study is to explore the markers in early prediction of the efficacy of pre-operative pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally advanced human epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.

cancer
ejection fraction
adjuvant therapy
pertuzumab + trastuzumab
primary tumor
  • 0 views
  • 16 Feb, 2024
  • 1 location
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed …

measurable disease
pemetrexed
carboplatin
paclitaxel
lung cancer
  • 0 views
  • 16 Feb, 2024
  • 41 locations
"CHOiCE"! Choose Health: Oncological Patients Cenetered Exercise

The program considers the preferences of EX of cancer survivors, giving the possibility to choose the EX modality (autonomous, with personal trainer or group class).

  • 0 views
  • 16 Feb, 2024
  • 2 locations